Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2014
04/01/2014US8685725 Monoclonal antibodies with enhanced ADCC function
04/01/2014US8685384 Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex
04/01/2014CA2655789C Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
04/01/2014CA2654318C Sulphimides as protein kinase inhibitors
04/01/2014CA2637302C Vitamin d analog-rak, methods and uses thereof
04/01/2014CA2633958C Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
04/01/2014CA2589521C Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
04/01/2014CA2567404C Cyclopenta[b]benzofuran derivatives and the utilization thereof
04/01/2014CA2544692C Anti-glypican 3 antibody
04/01/2014CA2493928C Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
04/01/2014CA2488682C Gene differentially expressed in breast and bladder cancer and encoded polypeptides
04/01/2014CA2488677C Method of inhibiting prostate cancer cell proliferation
04/01/2014CA2486483C Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
04/01/2014CA2423122C Closure of bacterial ghosts
03/2014
03/27/2014WO2014047648A1 Certain chemical entities, compositions, and methods
03/27/2014WO2014047588A1 Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
03/27/2014WO2014047426A1 Methods of treating hematological malignancies with notch1 antibodies
03/27/2014WO2014047398A1 Modulation of asymmetric proliferation
03/27/2014WO2014047392A1 Fluoroalkyl-1,4-benzodiazepinone compounds
03/27/2014WO2014047370A1 Fluoroalkyl dibenzodiazepinone compounds
03/27/2014WO2014047369A1 Substituted 1,5-benzodiazepinone compounds
03/27/2014WO2014047357A1 Modified fc polypeptides, fc conjugates, and methods of use thereof
03/27/2014WO2014047231A1 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
03/27/2014WO2014047199A1 Novel prodrugs for selective anticancer therapy
03/27/2014WO2014047169A1 Topical compositions comprising no and phosphatidycholine for cancer treatment
03/27/2014WO2014047109A1 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor
03/27/2014WO2014047024A1 Iap antagonists
03/27/2014WO2014047020A1 Dihydropyrrolidino-pyrimidines as kinase inhibitors
03/27/2014WO2014046983A1 Method of treating cancer
03/27/2014WO2014046732A1 Cyclotide-based cxcr4 antagonists with anti-hiv activity
03/27/2014WO2014046617A1 Compositions and methods for treating cancer
03/27/2014WO2014046589A1 Means and method for treating solid tumours
03/27/2014WO2014046441A1 Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same
03/27/2014WO2014046423A1 Peptide having cancer selective translocation function and use thereof
03/27/2014WO2014046143A1 Cell-growth inhibitor screening method indexed on inhibition of nptn-s100a8 binding
03/27/2014WO2014045561A1 Novel carotenoid
03/27/2014WO2014045310A1 Pyrimido[5,4-d]pyrimidine or pyrimidine derivatives compounds and uses thereof in the treatment of cancer
03/27/2014WO2014045305A1 Substituted fused tricyclic compounds, compositions and medicinal applications thereof
03/27/2014WO2014045279A1 Halobacteria extracts composition for tumor reduction
03/27/2014WO2014045101A1 Tetrazolo quinoxaline derivatives as tankyrase inhibitors
03/27/2014WO2014044846A1 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
03/27/2014WO2014044757A1 Cationic triphenylamine derivatives activable by visible and infra red light for inducing and imaging apoptosis in cancer cells
03/27/2014WO2014044755A1 4-(indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/27/2014WO2014044754A1 4-indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/27/2014WO2014044622A1 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
03/27/2014WO2014044399A1 New spiroepoxide tetrahydrobenzotriazoles and their use as metap-ii inhibitors
03/27/2014WO2014044356A1 Hydropyrrolopyrrole derivatives for use as fatty acid synthase inhibitors
03/27/2014WO2014044028A1 Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof
03/27/2014WO2014043866A1 Thiophene [2, 3-d] pyrimidine derivative, and preparation method and use thereof
03/27/2014WO2014019908A3 Substituted pyrroles active as kinases inhibitors
03/27/2014WO2013096335A8 ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
03/27/2014US20140088669 Particles
03/27/2014US20140088183 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
03/27/2014US20140088166 Process of making and using pharmaceutical formulations of antineoplastic agents
03/27/2014US20140088126 Rosuvastatin Enantiomer Compounds
03/27/2014US20140088108 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitiors
03/27/2014US20140088011 Softgel of NLKJ for treating prostate diseases
03/27/2014US20140087422 Nucleic acids related to fusion proteins
03/27/2014US20140087384 Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
03/27/2014US20140086972 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2014US20140086940 Herceptin® adjuvant therapy
03/27/2014US20140086935 Human TIMP-1 Antibodies
03/27/2014US20140086914 TREATMENT METHODS USING c-MET ANTIBODIES
03/27/2014DE102012018789A1 New N-isopropylcarbamate compound is phospholipase A2 inhibitor, useful for prophylactic and/or therapeutic treatment of diseases e.g. inflammation, psoriasis, cerebral ischemia, Alzheimer's disease, chronic skin diseases and thrombosis
03/27/2014CA2877188A1 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
03/26/2014EP2711704A1 Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
03/26/2014EP2711433A1 Method for predicting effectiveness of angiogenesis inhibitor
03/26/2014EP2711377A1 Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
03/26/2014EP2711376A1 Fgfr-fc fusion protein and use thereof
03/26/2014EP2711368A1 Benzoxazepin PI3K inhibitor compounds and methods of use
03/26/2014EP2711367A1 New spiroepoxide tetrahydrobenzo-triazoles and -imidazoles and their use as MetAP-II inhibitors
03/26/2014EP2711366A1 Cationic triphenylamine derivatives activable by visible and Infra Red light for inducing and imaging apoptosis in cancer cells
03/26/2014EP2711365A1 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/26/2014EP2711364A1 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
03/26/2014EP2711017A1 Immunity inducing agent
03/26/2014EP2711015A1 Immunity induction agent
03/26/2014EP2711010A1 Pharmaceutical composition
03/26/2014EP2711009A1 Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
03/26/2014EP2711008A1 N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
03/26/2014EP2711007A1 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
03/26/2014EP2711006A1 Product Comprising a Nicotine-Containing Material and an Anti-Cancer Agent
03/26/2014EP2711005A1 Compound dual-release capsule formulation comprised of bromodihydroarteisinin and fe2+ agent
03/26/2014EP2711000A1 Targeted Liposomes
03/26/2014EP2710042A2 Multi-specific fab fusion proteins and methods of use
03/26/2014EP2710040A1 Anti-human-her3 antibodies and uses thereof
03/26/2014EP2710039A2 Anti-cgrp compositions and use thereof
03/26/2014EP2710038A1 COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
03/26/2014EP2710037A2 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
03/26/2014EP2710027A1 Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
03/26/2014EP2710018A2 New compounds
03/26/2014EP2710017A2 Macrocycllc therapeutic agents and methods of treatment
03/26/2014EP2710007A2 Kinase inhibitors
03/26/2014EP2710005A1 Tyrosine kinase inhibitors
03/26/2014EP2710004A1 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
03/26/2014EP2710003A1 Fused bicyclic kinase inhibitors
03/26/2014EP2709999A1 Quinazoline-7-ether compounds and methods of use
03/26/2014EP2709996A1 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
03/26/2014EP2709990A1 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
03/26/2014EP2709975A1 Prenylated hydroxystilbenes
03/26/2014EP2709730A1 Treatment and prognosis of cancer
1 ... 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 ... 2211